Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV

Not Applicable

Completed

Interventions: Procedure: comparison of screening methods
Other: laboratory biomarker analysis
Other: questionnaire administration
Procedure: quality-of-life assessment

Brief Summary: This clinical trial studies anal human papillomavirus (HPV) tests in screening for cell changes in the anus in patients with human immunodeficiency virus (HIV). Screening tests may help doctors find cancer cells early and plan better treatment for anal cancer. Completing multiple screening tests may help find the best method for detecting cell changes in the anus.

Detailed Description: PRIMARY OBJECTIVES:

I. To determine the sensitivity and specificity of HPV testing using different methods of detection, including HPV Hybrid Capture 2 (HC2), HPV messenger ribonucleic acid (mRNA) assays (APTIMA) and OncoHealth HPV E6/E7 oncoprotein assay and whether they improve the screening performance of routine anal cytology for the detection of anal high-grade squamous intraepithelial lesions (HSIL) when measured against the gold standard, biopsy-proven HSIL.

II. To determine the prevalence and risk factors for prevalent HSIL in HIV-infected women.

III. To determine incidence and risk factors associated with anal HSIL and HPV over 2 years among HIV infected women undergoing semi-annual anal evaluations.

EXPLORATORY OBJECTIVES:

I. To evaluate the acceptability of anal cancer screening among HIV-infected women.

II. To collect data on quality of life and health care costs (including non-direct health care costs and time costs) for an economic evaluation of the cost-effectiveness of anal cancer screening strategies in HIV-positive women.

OUTLINE:

Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 12 and 24 months.

Recruitment & Eligibility

Inclusion Criteria

HIV positive; HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and Western blot, or other approved diagnostic tests
Karnofsky performance status > 70%
Absolute neutrophil count >= 750 cells/mm^3 within 120 days of study entry
Platelet count >= 75,000 cells/mm^3 within 120 days of study entry

Exclusion Criteria

Current or history of anal or perianal carcinoma
History of anal HSIL cytology or histology
Known permanent or irreversible bleeding disorder, or any illness that, in the opinion of the clinical investigator, would contraindicate any biopsy of the anal canal
For women able to conceive, evidence of pregnancy by a positive urinary pregnancy test; pregnant women are excluded from enrollment in this study
Serious medical or psychiatric illness that in the opinion of the site Investigator will interfere with the ability of the subject to give informed consent or adhere to the protocol
Ongoing use of anticoagulant therapy other than aspirin, clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDS)
Inability to provide informed consent
Treatment of anal and/or perianal HPV associated disease (i.e., condyloma or low-grade anal intraepithelial neoplasia [AIN]) within 4 months of study entry

Arm && Interventions

Group	Intervention	Description
Screening (HSIL detection)	comparison of screening methods	Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.
Screening (HSIL detection)	laboratory biomarker analysis	Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.
Screening (HSIL detection)	quality-of-life assessment	Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.
Screening (HSIL detection)	questionnaire administration	Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.

Primary Outcome Measures

Name	Time	Method
Specificity of Each Other Methods of HSIL Detection for APTIMA Assay	at baseline	Among patients who are HRA negative for HSIL, the number of participants who tested negative for HSIL on the APTIMA assay
Sensitivity of Each of the Methods of APTIMA Assay at Baseline	at baseline	Among patients whose high resolution anoscopy (HRA) results were positive for HSIL and had APTIMA assays at baseline, the number whose APTIMA assay results were positive.
Prevalence of HSIL	at baseline	The prevalence of HSIL will be estimated as the proportion of women who are HRA positive for HSIL at entry and its 95% confidence interval. Logistic regression analysis will be used to evaluate the association of potential risk factors with diagnosis of HSIL.
Incidence of HSIL Among Women Who Were HRA Negative for HSIL at Study Entry	Up to 2 years	The Poisson rate and its 95% confidence interval will be estimated from the number of HSIL cases detected divided by the cumulative years of follow-up across these cases.

Secondary Outcome Measures

Name	Time	Method
Acceptability of Anal Cancer Screening	at baseline	Anal cancer screening is typically done using a high resolution anoscopy, a device which allows visualization of the anus. To determine if participants found anal screening acceptable, they were asked if they were at east with having a high resolution anoscopy. The results indicated the number of participants who felt at ease with having a high resolution anoscopy

Locations (12): University of Pittsburgh School of Medicine
🇺🇸
Pittsburgh, Pennsylvania, United States
Beth Israel Deaconess Medical Center
🇺🇸
Boston, Massachusetts, United States
Baylor College of Medicine
🇺🇸
Houston, Texas, United States
John H. Stroger Hospital of Cook County
🇺🇸
Chicago, Illinois, United States
Boston University Cancer Research Center
🇺🇸
Boston, Massachusetts, United States
Ucsf Ancre
🇺🇸
San Francisco, California, United States
UCLA Clinical AIDS Research and Education (CARE) Center
🇺🇸
Los Angeles, California, United States
Weill-Cornell Medical College
🇺🇸
New York, New York, United States
Laser Surgery Care Center
🇺🇸
New York, New York, United States
Wake Forest University Health Sciences
🇺🇸
Winston-Salem, North Carolina, United States
University of Puerto Rico Comprehensive Cancer Center
🇵🇷
San Juan, Puerto Rico
Montefiore Medical Center
🇺🇸
Bronx, New York, United States